The U.S. Preventive Services Task Force (USPSTF) strongly recommends that clinicians discuss aspirin chemoprevention with adults who are at increased risk for coronary heart disease (CHD) (see "Clinical Considerations"). Discussions with patients should address both the potential benefits and harms of aspirin therapy. (A recommendation.)